Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAULA DENISE RYAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1043201015
CMS profile
506817
Location
SHENANDOAH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$18.29

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $18.29 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Ethicon US, LLC $18.29 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAULA DENISE RYAN

NPI 1043201015 · CMS profile ID 506817

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SHENANDOAH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043201015?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAULA DENISE RYAN, NPI 1043201015, CMS profile ID 506817. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043201015?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PAULA DENISE RYAN, NPI 1043201015, CMS profile ID 506817. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043201015?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PAULA DENISE RYAN, NPI 1043201015, CMS profile ID 506817, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1043201015?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $18.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ethicon US, LLC $18.2909/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718917123 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $18.29 1
PY2021 $11.92 1
PY2023 $25.00 1
PY2025 $1,412.91 21

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $315,099.41 8
PY2024 Principal investigator $85,021.48 15
PY2023 Principal investigator $225,702.19 11
PY2022 Principal investigator $147,633.72 41
PY2021 Principal investigator $205,086.85 25
PY2020 Principal investigator $157,982.23 26
PY2019 Recipient $4,222.00 1
PY2019 Principal investigator $179,621.19 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,397.95 12/31/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
Trastuzumab deruxtecan with pertuzumab-matching placebo No dispute reported 06/30/2026 914599933
Principal investigator 1 AstraZeneca Pharmaceuticals LP $728.77 12/31/2022 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Trastuzumab deruxtecan with pertuzumab-matching placebo No dispute reported 06/30/2026 914600553
Principal investigator 1 Eli Lilly and Company $22.00 11/15/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 917841799
Principal investigator 1 Genentech, Inc. $250.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
NSABP PROTOCOL B 59 GBG 96 GEPARDOUZE No dispute reported 06/30/2026 950692387
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 11/07/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935585323
Principal investigator 1 SANOFI US SERVICES INC. $2,479.00 10/17/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935585071
Principal investigator 1 Stemline Therapeutics Inc. $1,125.00 10/17/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 938583817
Principal investigator 1 Radius Health, Inc. $956.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 955002671
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 10/04/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935584983
Principal investigator 1 Eli Lilly and Company $13,396.00 08/30/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 917848087
Principal investigator 1 SANOFI US SERVICES INC. $1,551.00 08/22/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935584601
Principal investigator 1 Stemline Therapeutics Inc. $8,000.00 08/11/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 938583899
Principal investigator 1 SANOFI US SERVICES INC. $2,352.00 08/08/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935584313
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 08/08/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935584509
Principal investigator 1 Stemline Therapeutics Inc. $235.00 08/08/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 938583877
Principal investigator 1 SANOFI US SERVICES INC. $1,975.00 07/25/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935584107
Principal investigator 1 Radius Health, Inc. $956.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 955002839
Principal investigator 1 SANOFI US SERVICES INC. $66.00 07/11/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935584097
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,000.00 07/08/2022 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Trastuzumab deruxtecan with pertuzumab-matching placebo No dispute reported 06/30/2026 914599743
Principal investigator 1 Stemline Therapeutics Inc. $1,125.00 07/07/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 938583999
Principal investigator 1 SANOFI US SERVICES INC. $1,551.00 06/13/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935584443
Principal investigator 1 SANOFI US SERVICES INC. $1,904.00 05/16/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935583173
Principal investigator 1 Genentech, Inc. $150.00 05/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
NSABP PROTOCOL B 59 GBG 96 GEPARDOUZE No dispute reported 06/30/2026 950729417
Principal investigator 1 Radius Health, Inc. $1,125.00 05/05/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 955003159
Principal investigator 1 SANOFI US SERVICES INC. $1,711.00 04/18/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935582757
Principal investigator 1 Radius Health, Inc. $956.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 955002763
Principal investigator 1 SANOFI US SERVICES INC. $1,993.00 03/14/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935583591
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 03/07/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935583871
Principal investigator 1 SANOFI US SERVICES INC. $3,156.00 02/22/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935582496
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,047.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
Trastuzumab deruxtecan with pertuzumab-matching placebo No dispute reported 06/30/2026 914597453
Principal investigator 1 SANOFI US SERVICES INC. $1,711.00 02/14/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935583475
Principal investigator 1 SANOFI US SERVICES INC. $6,580.00 02/02/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935582119
Principal investigator 1 SANOFI US SERVICES INC. $2,666.00 02/02/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935582211
Principal investigator 1 Radius Health, Inc. $1,125.00 01/20/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 955003221
Principal investigator 1 SANOFI US SERVICES INC. $5,377.00 01/18/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935583103
Principal investigator 1 Eli Lilly and Company $3,824.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 917834557
Principal investigator 1 Eli Lilly and Company $10,368.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 917844367
Principal investigator 1 Eli Lilly and Company $28,884.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 917847259
Principal investigator 1 Radius Health, Inc. $956.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 955002611
Principal investigator 1 Eli Lilly and Company $152.00 01/14/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 917847103
Principal investigator 1 SANOFI US SERVICES INC. $283.00 01/04/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935581761